# Lexeo Therapeutics (LXEO) — News

LXEO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lxeo/news

## Recent headlines

- [Lexeo Therapeutics to buy Mantle Therapeutics](https://www.ainvest.com/news/lexeo-therapeutics-buy-mantle-therapeutics-2609) — AInvest Wire, Sep 22, 2026
- [Lexo Therapeutics: Deal includes up to $13 mln in milestone payments, total potential $21.30 mln](https://www.ainvest.com/news/lexo-therapeutics-deal-includes-13-mln-milestone-payments-total-potential-21-30-mln-2609) — AInvest Wire, Sep 22, 2026
  Lexeo Therapeutics, Inc. (Nasdaq: LXEO) has disclosed a deal structure that includes up to $13 million in milestone payments, with a total potential value of $21.3 million. The company has not provided specific details regarding the nature of the agreement or the conditions under which the…
- [Lexeo Therapeutics, - To pay $8.30 mln upfront to Mantle shareholders](https://www.ainvest.com/news/lexeo-therapeutics-pay-8-30-mln-upfront-mantle-shareholders-2609) — AInvest Wire, Sep 22, 2026
- [Lexeo: Sunrise-FA 2 study for LX2006 on track to initiate in 2Q](https://www.ainvest.com/news/lexeo-sunrise-fa-2-study-lx2006-track-initiate-2q-2606) — AInvest Wire, Jun 17, 2026
  Lexeo Therapeutics is progressing with its clinical development program for LX2006, an AAV-based gene therapy candidate for Friedreich’s ataxia cardiomyopathy. Following positive interim data from the ongoing Phase 1/2 SUNRISE-FA trial and alignment with the FDA on key parameters for the…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).